Grant from Cancer Society

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES
eliminating the need for prophylactiC antibiotics
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

HOME
News
Grant from Cancer Society

Grant from Cancer Society

Akthelia founder awarded

June 6, 2022

Akthelia's founder Guðmundur Hrafn Guðmundsson was recently awarded a grant from the Icelandic Cancer Society to fund research into prophylactic therapies for febrile neutropenia..

More information on the Society's web site.

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

Grant from Cancer Society

Akthelia founder awarded

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis